Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: follow-up through Month 48 in a Phase III randomized study.
Hum Vaccin Immunother
; 10(12): 3455-65, 2014.
Article
en En
| MEDLINE
| ID: mdl-25483700
Palabras clave
50 µg) adsorbed on aluminum salt (500 µg Al(OH)3); ANOVA, analysis of variance; AS04, Adjuvant System containing 3-O-desacyl-4'-monophosphoryl lipid A (MPL; ATP, according-to-protocol; CI, confidence interval; CMI, cell-mediated immune; CVS, cervicovaginal secretion; Cervarix®; ED50, effective dose producing 50% response; ELISA, enzyme-linked immunosorbent assay; GM, geometric mean; GMR, geometric mean (titer) ratio; GMT, geometric mean titer; Gardasil®; HPA, Health Protection Agency; HPV, human papillomavirus; IgG, immunoglobulin G; MSC, medically significant condition; NOAD, new onset autoimmune disease; NOCD, new onset chronic disease; PBMC, peripheral blood mononuclear cells; PBNA, pseudovirion-based neutralization assay; SAE, serious adverse event; TVC, total vaccinated cohort; VLP, virus-like particle; human papillomavirus; immunogenicity; nAb(s), neutralizing antibody(ies); safety
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Vacunas contra Papillomavirus
Tipo de estudio:
Clinical_trials
/
Guideline
/
Observational_studies
/
Prognostic_studies
Límite:
Adolescent
/
Adult
/
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Hum Vaccin Immunother
Año:
2014
Tipo del documento:
Article
Pais de publicación:
Estados Unidos